Cardiovascular Disease and Risk Factors in PCOS Women of Postmenopausal Age: A 21-Year Controlled Follow-Up Study
The DOI matches its Crossref record; 43 of the 44 references it cites were found in a registry or an index.
Abstract
CONTEXT: Polycystic ovary syndrome (PCOS) is associated with the metabolic syndrome and, consequently, with a potentially increased risk of cardiovascular disease (CVD) and related mortality later in life. Studies regarding CVD and mortality in PCOS women well into the postmenopausal age are lacking. OBJECTIVE: Our objective was to examine whether postmenopausal PCOS women differ from controls regarding cardiovascular risk factors, myocardial infarction (MI), stroke and mortality. DESIGN AND SETTING: We conducted, at a university hospital, a prospective study of 35 PCOS women (61-79 yr) and 120 age-matched controls. The study was performed 21 yr after the initial study. PARTICIPANTS: Twenty-five PCOS women (Rotterdam criteria) and 68 controls participated in all examinations. Data on morbidity were based on 32 of 34 PCOS women and on 95 of 119 controls. INTERVENTIONS: INTERVENTIONS included reexamination, interviews, and data from the National Board of Health and Welfare and from the Hospital Discharge Registry. MAIN OUTCOME MEASURES: Blood pressure, glucose, insulin, triglycerides, total cholesterol, high- and low-density lipoprotein, apolipoprotein A1 and B, fibrinogen, and plasminogen activator inhibitor antigen were studied. Incidences of MI, stroke, hypertension, diabetes, cancer, cause of death, and age at death were recorded. RESULTS: PCOS women had a higher prevalence of hypertension (P = 0.008) and higher triglyceride levels (P = 0.012) than controls. MI, stroke, diabetes, cancer, and mortality prevalence was similar in the two cohorts with similar body mass index. CONCLUSIONS: The well-described cardiovascular/metabolic risk profile in pre- and perimenopausal PCOS women does not entail an evident increase in cardiovascular events during the postmenopausal period.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“PCOS is linked with increased prevalence of cardiometabolic risk factors, including dyslipidemia [10,11,12,13], hypertension [13,14,15], chronic inflammation, and impaired glucose tolerance [16,17], as well as overweight and obesity [18,19].”
From Moving beyond Weight: A Narrative Review of the Dietary and Lifestyle Management for Reducing Cardiometabolic Risk in Polycystic Ovary Syndrome (PCOS) (2023) · cites this paper as [13]
In the citing paper
“Women with PCOS experience increased cardiometabolic risk—including the metabolic syndrome, hypertension, insulin resistance, obesity and dyslipidemia—predisposing them to increased risk for diabetes and cardiovascular disease (CVD).2,10,17, 18, 19, 20”
From Increased Prevalence of Adverse Health Outcomes Across the Lifespan in Those Affected by Polycystic Ovary Syndrome: A Canadian Population Cohort (2024) · cites this paper as [20]
In the citing paper
“The results regarding prevalence of T2DM in women with PCOS over the age of 40 years are conflicting.”
From Type 2 diabetes mellitus in women with polycystic ovary syndrome during a 24-year period: importance of obesity and abdominal fat distribution (2020) · cites this paper as Schmidt et al., 2011
In the citing paper
“The lack of significance might be due to the similar BMI between groups in that study and the fact that controls caught up in WHR during the 21-year follow-up period (Schmidt et al., 2011).”
From Type 2 diabetes mellitus in women with polycystic ovary syndrome during a 24-year period: importance of obesity and abdominal fat distribution (2020) · cites this paper as Schmidt et al., 2011
In the citing paper
“In our previous study of another cohort of women with PCOS and controls, where the women had a mean age of 72 years and similar BMI, the prevalence of T2DM was 22% for women with PCOS compared with 14% for controls (not statistically significant) (Schmidt et al., 2011).”
From Type 2 diabetes mellitus in women with polycystic ovary syndrome during a 24-year period: importance of obesity and abdominal fat distribution (2020) · cites this paper as Schmidt et al., 2011
Citations
Cites
1 retracted
Shaw, L. J., Bairey Merz, C. N., Azziz, R., Stanczyk, F. Z., Sopko, G., Braunstein, G. D., Kelsey, S. F., Kip, K. E., Cooper-DeHoff, R. M., Johnson, B. D., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0425 · Cited by 427
RetractedGrundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Yusuf, S., Hawken, S., Ôunpuu, S., Dans, T., Avezum, A., Lanas, F., McQueen, M., Budaj, A., Pais, P., Varigos, J., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17018-9 · Cited by 12,026
(2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.10.004 · Cited by 9,050
Cardiovascular Morbidity and Mortality Associated With the Metabolic Syndrome
Isomaa, B., Almgren, P., Tuomi, T., Forsén, B., Lahti, K., Nissén, M., Taskinen, M.-R., & Groop, L. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.683 · Cited by 4,760 · cited 1×
“risk of diabetes mellitus, cardiovascular disease (CVD) (13) and all-cause mortality (14).”
BackgroundGerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens
Clauss, A. (1957) · Acta Haematologica · doi:10.1159/000205234 · Cited by 3,208
Men at risk: occupation and male infertility
Claman, P. (2004) · Fertility and Sterility · doi:10.1016/s0015-0282(03)01188-9 · Cited by 2,387
Profound Peripheral Insulin Resistance, Independent of Obesity, in Polycystic Ovary Syndrome
Dunaif, A., Segal, K. R., Futterweit, W., & Dobrjansky, A. (1989) · Diabetes · doi:10.2337/diab.38.9.1165 · Cited by 1,967
Legro, R. S. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.1.165 · Cited by 1,743 · cited 2×
“Diabetes, a strong risk factor for CVD, as well as insulin resistance and hyperinsulinemia are common among PCOS women of premenopausal (2, 4) and perimenopausal/early postmenopausal age (9, 17).”
BackgroundWalldius, G., Jungner, I., Holme, I., Aastveit, A. H., Kolar, W., & Steiner, E. (2001) · The Lancet · doi:10.1016/s0140-6736(01)07098-2 · Cited by 1,229
Cited by
Azziz, R., Carmina, E., Chen, Z., Dunaif, A., Laven, J. S. E., Legro, R. S., Lizneva, D., Natterson-Horowtiz, B., Teede, H. J., & Yildiz, B. O. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.57 · Cited by 2,005
Legro, R. S., Arslanian, S. A., Ehrmann, D. A., Hoeger, K. M., Murad, M. H., Pasquali, R., & Welt, C. K. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2350 · Cited by 1,919
Epidemiology, diagnosis, and management of polycystic ovary syndrome
Sirmans, S., & Pate, K. (2013) · Clinical Epidemiology · doi:10.2147/clep.s37559 · Cited by 1,302
“previously did not demonstrate an increase in cardiovascular events compared to 120 age-matched controls.(87) In contrast,”
ResultThe polycystic ovary syndrome: a position statement from the European Society of Endocrinology
Conway, G., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H. F., Franks, S., Gambineri, A., Kelestimur, F., Macut, D., Micic, D., Pasquali, R., et al. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0253 · Cited by 676
“In addition, some of the available reports also imply that PCOS sequelae continue post-menopause (22, 23, 24, 25), namely in subjects diagnosed with the strict NIH criteria (4).”
Sex differences in cardiovascular risk factors and disease prevention
Appelman, Y., van Rijn, B. B., ten Haaf, M. E., Boersma, E., & Peters, S. A. E. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.01.027 · Cited by 588
Long-term cardiometabolic disease risk in women with PCOS: a systematic review and meta-analysis
Wekker, V, van Dammen, L., Koning, A., Heida, K. Y., Painter, R. C., Limpens, J., Laven, J. S. E., Roeters van Lennep, J. E., Roseboom, T. J., & Hoek, A. (2020) · Human Reproduction Update · doi:10.1093/humupd/dmaa029 · Cited by 425
“Five studies (Talbott et al., 1995; Cibula et al., 2000; Schmidt et al., 2011; Hudecova et al., 2011a,b; Carmina et al., 2013) were included in the meta-analysis for TG concentration (mg/dl).”
BackgroundMethodInfluentialPolycystic ovarian syndrome (PCOS): Long-term metabolic consequences
Anagnostis, P., Tarlatzis, B. C., & Kauffman, R. P. (2018) · Metabolism · doi:10.1016/j.metabol.2017.09.016 · Cited by 416
Gender differences in cardiovascular disease
Gao, Z., Chen, Z., Sun, A., & Deng, X. (2019) · Medicine in Novel Technology and Devices · doi:10.1016/j.medntd.2019.100025 · Cited by 373
Goodman, N. F., Cobin, R. H., Futterweit, W., Glueck, J. S., Legro, R. S., & Carmina, E. (2015) · Endocrine Practice · doi:10.4158/ep15748.dscpt2 · Cited by 359
Regensteiner, J. G., Golden, S., Huebschmann, A. G., Barrett-Connor, E., Chang, A. Y., Chyun, D., Fox, C. S., Kim, C., Mehta, N., Reckelhoff, J. F., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000343 · Cited by 334
“The study that initially reported a 7-fold predicted risk for cardiovascular events with a sample of 35 women with PCOS(125) found no increase in cardiovascular events after 21 years of follow-up.(126) Another cohort with a similar length of followup in a retrospective sample of 309 women with PCOS also found no incre…”
BackgroundPoly Cystic Ovarian Syndrome: An Updated Overview
El Hayek, S., Bitar, L., Hamdar, L. H., Mirza, F. G., & Daoud, G. (2016) · Frontiers in Physiology · doi:10.3389/fphys.2016.00124 · Cited by 323
Cardiometabolic Aspects of the Polycystic Ovary Syndrome
Randeva, H. S., Tan, B. K., Weickert, M. O., Lois, K., Nestler, J. E., Sattar, N., & Lehnert, H. (2012) · Endocrine Reviews · doi:10.1210/er.2012-1003 · Cited by 322
Complications and challenges associated with polycystic ovary syndrome: current perspectives
Palomba, S., Santagni, S., Falbo, A., & La Sala, G. B. (2015) · International Journal of Women's Health · doi:10.2147/ijwh.s70314 · Cited by 287
Beyond fertility: polycystic ovary syndrome and long-term health
Cooney, L. G., & Dokras, A. (2018) · Fertility and Sterility · doi:10.1016/j.fertnstert.2018.08.021 · Cited by 270
Daan, N. M. P., Louwers, Y. V., Koster, M. P. H., Eijkemans, M. J. C., de Rijke, Y. B., Lentjes, E. W. G., Fauser, B. C. J. M., & Laven, J. S. E. (2014) · Fertility and Sterility · doi:10.1016/j.fertnstert.2014.08.001 · Cited by 217
Riestenberg, C., Jagasia, A., Markovic, D., Buyalos, R. P., & Azziz, R. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab613 · Cited by 210
Polycystic ovary syndrome: a “risk-enhancing” factor for cardiovascular disease
Guan, C., Zahid, S., Minhas, A. S., Ouyang, P., Vaught, A., Baker, V. L., & Michos, E. D. (2022) · Fertility and Sterility · doi:10.1016/j.fertnstert.2022.03.009 · Cited by 188
Ollila, M.-M. E., Piltonen, T., Puukka, K., Ruokonen, A., Järvelin, M.-R., Tapanainen, J. S., Franks, S., & Morin-Papunen, L. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3543 · Cited by 182
“Previous studies have demonstrated that women with PCOS have a worse metabolic profile, including elevated triglyceride levels that are already apparent at a young age and are independent of obesity (12, 13).”
BackgroundAssessing and Addressing Social Determinants of Cardiovascular Health
Brandt, E. J., Tobb, K., Cambron, J. C., Ferdinand, K. C., Douglass, P., Nguyen, P. K. P., Vijayaraghavan, K., Islam, S., Thamman, R., Rahman, S., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.01.042 · Cited by 178
Metabolic disorders in menopause
Stachowiak, G., Pertyński, T., & Pertyńska-Marczewska, M. (2015) · Menopausal Review · doi:10.5114/pm.2015.50000 · Cited by 130
“Therefore, the welldescribed cardiovascular/metabolic risk profile in preand perimenopausal PCOS women does not entail an evident increase in cardiovascular events during the postmenopausal period [30].”
BackgroundPolycystic ovary syndrome (PCOS) and the risk of coronary heart disease (CHD): a meta-analysis.
Zhao, L., Zhu, Z., Lou, H., Zhu, G., Huang, W., Zhang, S., & Liu, F. (2016) · Oncotarget · doi:10.18632/oncotarget.9553 · Cited by 174
“However, the results are controversial [7-16].”
Characteristics of polycystic ovary syndrome throughout life
Louwers, Y. V., & Laven, J. S. E. (2020) · Therapeutic Advances in Reproductive Health · doi:10.1177/2633494120911038 · Cited by 174
Nonalcoholic fatty liver disease and polycystic ovary syndrome
Vassilatou, E. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i26.8351 · Cited by 173
Newman, C. B., Blaha, M. J., Boord, J. B., Cariou, B., Chait, A., Fein, H. G., Ginsberg, H. N., Goldberg, I. J., Murad, M. H., Subramanian, S., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa674 · Cited by 172
MECHANISMS IN ENDOCRINOLOGY: The sexually dimorphic role of androgens in human metabolic disease
Schiffer, L., Kempegowda, P., Arlt, W., & O’Reilly, M. W. (2017) · European Journal of Endocrinology · doi:10.1530/eje-17-0124 · Cited by 151
Almenning, I., Rieber-Mohn, A., Lundgren, K. M., Shetelig Løvvik, T., Garnæs, K. K., & Moholdt, T. (2015) · PLOS ONE · doi:10.1371/journal.pone.0138793 · Cited by 155
Schmidt, J., Weijdegard, B., Mikkelsen, A. L., Lindenberg, S., Nilsson, L., & Brannstrom, M. (2014) · Molecular Human Reproduction · doi:10.1093/molehr/gat051 · Cited by 123
“Height and body weight were measured according to standard procedures described previously (Schmidt et al., 2011).”
MethodSelf-citationAmiri, M., Ramezani Tehrani, F., Behboudi-Gandevani, S., Bidhendi-Yarandi, R., & Carmina, E. (2020) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-020-00576-1 · Cited by 136
Sprung, V. S., Atkinson, G., Cuthbertson, D. J., Pugh, C. J. A., Aziz, N., Green, D. J., Cable, N. T., & Jones, H. (2013) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2012.04490.x · Cited by 142
Tay, C. T., Mousa, A., Vyas, A., Pattuwage, L., Tehrani, F. R., & Teede, H. J. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.033572 · Cited by 155
“Diagnosis in the included studies mostly relied on National Institutes of Health criteria (n=6), 22,25,27,36,37,43 Rotterdam criteria (n=6), 23,34,35,38,39,42 or identification through medical records or ICD codes (n=7).”
Lifecycle of polycystic ovary syndrome (PCOS): from in utero to menopause
Welt, C. K., & Carmina, E. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2375 · Cited by 148
“There has been only one small longitudinal study and one retrospective cohort study in women diagnosed with PCOS in their reproductive years and controls to assess risk of mortality and cardiovascular morbidity into menopause, up to age 70 years (76, 77).”
BackgroundResultInfluentialBerni, T. R., Morgan, C. L., & Rees, D. A. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab392 · Cited by 146
“Other population-based studies have been limited by comparatively small sample sizes and/or a failure to adjust for important confounders such as obesity (13-20).”
BackgroundFernandez, R., Moore, V., Van Ryswyk, E., Varcoe, T., Rodgers, R., March, W., Moran, L., Avery, J., McEvoy, D., & Davies, M. (2018) · Nature and Science of Sleep · doi:10.2147/nss.s127475 · Cited by 137
“Another study with a small sample size and substantial losses to follow-up over 21 years found more hypertension and higher triglycerides in women with PCOS (n = 25 of 35) compared to women of similar age and BMI (n = 68 of 120).(156) Turning to the wider literature, a recent meta-analysis of cohort studies showed tha…”
ResultCardiovascular disease risk in women with PCOS
Dokras, A. (2013) · Steroids · doi:10.1016/j.steroids.2013.04.009 · Cited by 132
Polycystic ovary syndrome and type 2 diabetes mellitus: A state-of-the-art review
Livadas, S., Anagnostis, P. G., Bosdou, J. Κ., Bantouna, D., & Paparodis, R. D. (2022) · World Journal of Diabetes · doi:10.4239/wjd.v13.i1.5 · Cited by 131
Ollila, M.-M., Arffman, R. K., Korhonen, E., Morin-Papunen, L., Franks, S., Junttila, J., & Piltonen, T. T. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvad077 · Cited by 108
MANAGEMENT OF ENDOCRINE DISEASE: Hyperandrogenism after menopause
Markopoulos, M. C., Kassi, E., Alexandraki, K. I., Mastorakos, G., & Kaltsas, G. (2015) · European Journal of Endocrinology · doi:10.1530/eje-14-0468 · Cited by 105
Duică, F., Dănilă, C. A., Boboc, A. E., Antoniadis, P., Condrat, C. E., Onciul, S., Suciu, N., Creţoiu, S. M., Varlas, V. N., & Crețoiu, D. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.614679 · Cited by 114
“These disturbances are represented primarily by atherogenic dyslipidemia, hypertension, obesity, along with insulin resistance, impaired glucose tolerance and type II diabetes (94, 95).”
BackgroundZhang, J., Xu, J.-H., Qu, Q.-Q., & Zhong, G.-Q. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.552421 · Cited by 96
Ramezani Tehrani, F., Amiri, M., Behboudi-Gandevani, S., Bidhendi-Yarandi, R., & Carmina, E. (2020) · Gynecological Endocrinology · doi:10.1080/09513590.2019.1650337 · Cited by 91
“Five studies reported CAD [18,29,32,35,37], four cerebrovascular disease [18,30–32], six CVD [30,33,35,36,39,41], seven MI [30,33,36,37,39–41], three angina [33,37,39], five stroke [30,36,37,39,41], one heart failure [37], one ischemic heart disease [31], and three mortalities due to CV events [19,34,39].”
BackgroundMethodInfluentialMetabolic Syndrome During Menopause
Mümüşoğlu, S., & Yıldız, B. O. (2018) · Current Vascular Pharmacology · doi:10.2174/1570161116666180904094149 · Cited by 100
de Melo, A. S., Dias, S. V., Cavalli, R. D. C., Cardoso, V. C., Bettiol, H., Barbieri, M. A., Ferriani, R. A., & Vieira, C. S. (2015) · Reproduction · doi:10.1530/rep-14-0499 · Cited by 99
“…stroke was observed in menopausal PCOS women (OR, 1.94; 95% CI, 1.19–3.17) (Anderson et al. 2014), but no increased risk for acute myocardial infarction and/or mortality caused by cardiovascular events in women aged 61–79 years was observed during a 21-year follow-up (Schmidt et al. 2011).”
InfluentialPolycystic ovary syndrome: A review for dermatologists
Housman, E., & Reynolds, R. V. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.05.007 · Cited by 95
Huang, Y., & Zhang, X. (2021) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00034.2021 · Cited by 85
PCOS during the menopausal transition and after menopause: a systematic review and meta-analysis
Millán-de-Meer, M., Luque-Ramírez, M., Nattero-Chávez, L., & Escobar-Morreale, H. F. (2023) · Human Reproduction Update · doi:10.1093/humupd/dmad015 · Cited by 82
Kazemi Jaliseh, H., Ramezani Tehrani, F., Behboudi-Gandevani, S., Hosseinpanah, F., Khalili, D., Cheraghi, L., & Azizi, F. (2017) · Fertility and Sterility · doi:10.1016/j.fertnstert.2017.09.004 · Cited by 80
Challenges in diagnosis and understanding of natural history of polycystic ovary syndrome
Joham, A. E., Piltonen, T., Lujan, M. E., Kiconco, S., & Tay, C. T. (2022) · Clinical Endocrinology · doi:10.1111/cen.14757 · Cited by 80
“Psychological comorbidity is the most recently understood association of PCOS with abundance of evidence showing increased prevalence of psychological distress, sexual dysfunction, mood disorders, eating disorders, personality disorders and even frank psychiatric disorders in women with PCOS.7,8,67 Potential aetiologi…”
BackgroundInfluentialInsulin resistance: a risk marker for disease and disability in the older person
Krentz, A. J., Viljoen, A., & Sinclair, A. J. (2013) · Diabetic Medicine · doi:10.1111/dme.12063 · Cited by 81
Are women with polycystic ovary syndrome at increased cardiovascular disease risk later in life?
Gunning, M. N., & Fauser, B. C. J. M. (2017) · Climacteric · doi:10.1080/13697137.2017.1316256 · Cited by 71
“After re-analysis of these data and extended follow-up, no significant difference was found in CVD between women with PCOS and healthy controls 38 .”
An Update on Contraception in Polycystic Ovary Syndrome
Oguz, S. H., & Yildiz, B. O. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2021.958 · Cited by 76
“However, the evidence remains controversial regarding whether there is an absolute increase in risk for MI, stroke, cardiovascular death, or coronary heart disease in women with PCOS in the long-term [58,59], including peri- and postmenopausal periods [60-63].”
BackgroundCardiometabolic risk in polycystic ovary syndrome
Bajuk Studen, K., & Pfeifer, M. (2018) · Endocrine Connections · doi:10.1530/ec-18-0129 · Cited by 64
Polycystic Ovarian Syndrome: Long-Term Health Consequences
Zore, T., Joshi, N., Lizneva, D., & Azziz, R. (2017) · Seminars in Reproductive Medicine · doi:10.1055/s-0037-1603096 · Cited by 72
Lipid profiles and ovarian reserve status: a longitudinal study
Tehrani, F. R., Erfani, H., Cheraghi, L., Tohidi, M., & Azizi, F. (2014) · Human Reproduction · doi:10.1093/humrep/deu249 · Cited by 71
Ismayilova, M., & Yaya, S. (2022) · BMC Women's Health · doi:10.1186/s12905-022-01630-3 · Cited by 68
“In addition to infertility, patients with PCOS have greater rates of obesity [4], type 2 diabetes [5], metabolic syndrome [6, 7], cardiovascular risk factors such as hypertension [8, 9], poor body image [10, 11], eating disorders [12–14], anxiety and depression [15–17].”
BackgroundThe cardiovascular risk profile of middle‐aged women with polycystic ovary syndrome
Meun, C., Gunning, M. N., Louwers, Y. V., Peters, H., Roos‐Hesselink, J., Roeters van Lennep, J., Rueda Ochoa, O., Appelman, Y., Lambalk, N., Boersma, E., et al. (2020) · Clinical Endocrinology · doi:10.1111/cen.14117 · Cited by 65
Ramezani Tehrani, F., Montazeri, S. A., Hosseinpanah, F., Cheraghi, L., Erfani, H., Tohidi, M., & Azizi, F. (2015) · PLOS ONE · doi:10.1371/journal.pone.0137609 · Cited by 67
“women [7,10,33], others concluded no evidence of different CVD outcomes between the two groups [8,9,11].”
BackgroundInfluentialForslund, M., Landin-Wilhelmsen, K., Trimpou, P., Schmidt, J., Brännström, M., & Dahlgren, E. (2020) · Human Reproduction Open · doi:10.1093/hropen/hoz042 · Cited by 66
“similar BMI between groups in that study and the fact that controls caught up in WHR during the 21-year follow-up period (Schmidt et al., 2011).”
BackgroundSelf-citationDyslipidemia in midlife women: Approach and considerations during the menopausal transition
Torosyan, N., Visrodia, P., Torbati, T., Minissian, M., & SHUFELT, C. L. (2022) · Maturitas · doi:10.1016/j.maturitas.2022.08.001 · Cited by 66
MANAGEMENT OF ENDOCRINE DISEASE: Polycystic ovary syndrome and nonalcoholic fatty liver disease
Μacut, D., Antić, I. B., Bjekić-Macut, J., & Τζιόμαλος, Κ. (2017) · European Journal of Endocrinology · doi:10.1530/eje-16-1063 · Cited by 66
Cardiac autonomic modulation in polycystic ovary syndrome: does the phenotype matter?
Domenico, K. D., Wiltgen, D., Nickel, F. J., Magalhães, J. A. D. A., Moraes, R. S., & Spritzer, P. M. (2012) · Fertility and Sterility · doi:10.1016/j.fertnstert.2012.08.049 · Cited by 65
Forslund, M., Landin‐Wilhelmsen, K., Schmidt, J., Brännström, M., Trimpou, P., & Dahlgren, E. (2019) · Acta Obstetricia Et Gynecologica Scandinavica · doi:10.1111/aogs.13489 · Cited by 60
Self-citationPolycystic ovary syndrome: a common reproductive syndrome with long-term metabolic consequences
Yau, T., Ng, N. Y. H., Cheung, L., & Ronald, C. W. (2017) · Hong Kong Medical Journal · doi:10.12809/hkmj176308 · Cited by 59
Ollila, M.-M. E., Kaikkonen, K., Järvelin, M.-R., Huikuri, H. V., Tapanainen, J. S., Franks, S., Piltonen, T. T., & Morin-Papunen, L. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00570 · Cited by 53
“Of note, previous studies have been limited with small number of study subjects (n=14–36) (6-10).”
BackgroundResultPolycystic ovary syndrome and aging: Health implications after menopause
Helvacı, N., & Yıldız, B. O. (2020) · Maturitas · doi:10.1016/j.maturitas.2020.05.013 · Cited by 55
Cardiometabolic Risk in Polycystic Ovary Syndrome
Cooney, L. G., & Dokras, A. (2021) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2020.11.001 · Cited by 44
“The guidelines also suggest considering the use of metformin in women with PCOS with BMI greater than or equal to 25 kg/m2 without IGT/DM,14 Metformin has been shown to decrease progression from IGT to DM in the general population30 and to decrease BMI in women with PCOS.31”
BackgroundInfluentialVine, D., Ghosh, M., Wang, T., & Bakal, J. (2024) · CJC Open · doi:10.1016/j.cjco.2023.12.010 · Cited by 53
Bener, A., & Falah, A. (2014) · Journal of Mid-life Health · doi:10.4103/0976-7800.141190 · Cited by 53
“[4] These fluctuations cause many of the physical changes during perimenopause as well as menopause.[2-18] Some of these changes are hot flashes, night sweats, difficulty sleeping, vaginal dryness or atrophy, incontinence, osteoporosis, and heart disease.”
BackgroundResultInfluentialKataoka, J., Larsson, I., Björkman, S., Eliasson, B., Schmidt, J., & Stener‐Victorin, E. (2019) · Clinical Endocrinology · doi:10.1111/cen.14098 · Cited by 52
Self-citationHyperandrogenic Oligomenorrhea and Metabolic Risks Across Menopausal Transition
Polotsky, A. J., Allshouse, A. A., Crawford, S. L., Harlow, S. D., Khalil, N., Kazlauskaite, R., Santoro, N., & Legro, R. S. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-4170 · Cited by 47
Anagnostis, P. G., Paparodis, R. D., Bosdou, J. Κ., Bothou, C., Μacut, D., Goulis, D. G., & Livadas, S. (2021) · Endocrine · doi:10.1007/s12020-021-02801-2 · Cited by 52
Nybacka, Å., Hellström, P. M., & Hirschberg, A. L. (2017) · Clinical Endocrinology · doi:10.1111/cen.13427 · Cited by 50
Hepatic manifestations of women with polycystic ovary syndrome
Chen, M., & Ho, H. (2016) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2016.03.003 · Cited by 51
Cardiometabolic risks in polycystic ovary syndrome: long-term population-based follow-up study
Behboudi-Gandevani, S., Ramezani Tehrani, F., Hosseinpanah, F., Khalili, D., Cheraghi, L., Kazemijaliseh, H., & Azizi, F. (2018) · Fertility and Sterility · doi:10.1016/j.fertnstert.2018.08.046 · Cited by 46
Polycystic Ovary Syndrome, Insulin Resistance, and Cardiovascular Disease
Dubey, P., Reddy, S., Sharma, K., Johnson, S., Hardy, G., & Dwivedi, A. K. (2024) · Current Cardiology Reports · doi:10.1007/s11886-024-02050-5 · Cited by 51
“…analysis of the Swedish study participants in an extended prospective follow-up study [21 years after recruitment] design failed to show an increased risk of MI, stroke, or CVD-related death in postmenopausal women with PCOS compared to age-matched controls with similar BMI between the groups [66].”
Cardiometabolic biomarkers in women with polycystic ovary syndrome
van der Ham, K., Louwers, Y. V., & Laven, J. S. E. (2022) · Fertility and Sterility · doi:10.1016/j.fertnstert.2022.03.008 · Cited by 49
Schmidt, J., Dahlgren, E., Brännström, M., & Landin‐Wilhelmsen, K. (2012) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2012.04378.x · Cited by 48
Self-citationSingh, V., Mahra, K., Jung, D.-R., & Shin, J. (2024) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-024-10262-y · Cited by 47
“Women with PCOS have higher levels of low-density cholesterol (LDL) and lower levels of high-density cholesterol (HDL), as well as decreased triglyceride levels [119, 120].”
Livadas, S., Κόλλιας, Α., Panidis, D., & Diamanti‐Kandarakis, E. (2014) · European Journal of Endocrinology · doi:10.1530/eje-13-1007 · Cited by 47
Kujanpää, L., Arffman, R. K., Pesonen, P., Korhonen, E., Karjula, S., Järvelin, M., Franks, S., Tapanainen, J. S., Morin‐Papunen, L., & Piltonen, T. T. (2022) · Acta Obstetricia et Gynecologica Scandinavica · doi:10.1111/aogs.14382 · Cited by 40
Polycystic Ovary Syndrome as a Paradigm for Prehypertension, Prediabetes, and Preobesity
Luque‐Ramírez, M., & Escobar-Morreale, H. F. (2014) · Current Hypertension Reports · doi:10.1007/s11906-014-0500-6 · Cited by 45
Study of early atherosclerotic markers in women with polycystic ovary syndrome
Karoli, R., Fatima, J., Siddiqi, Z., Vatsal, P., Sultania, A., & Maini, S. (2012) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.103021 · Cited by 44
“The insulin resistance is the key component of PCOS, which is present in both obese and lean women with PCOS[28] and is linked with the increased cardiovascular risk markers.”
Sprung, V. S., Jones, H., Pugh, C. J. A., Aziz, N., Daousi, C., Kemp, G. J., GREEN, D. J., Cable, N. T., & Cuthbertson, D. J. (2013) · Clinical Science · doi:10.1042/cs20130186 · Cited by 44
Polycystic ovary syndrome and the risk of cardiometabolic complications in longitudinal studies
Jacewicz‐Święcka, M., & Kowalska, I. (2018) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3054 · Cited by 38
“A progressive, significant rise in waist circumference WC in PCOS women was observed in an Italian study, in which controls were not followed.78 Significantly greater WC was found by the group of researchers from Finland in women with PCOS compared with controls, both at ages 31 and 46.79 Surprisingly, no significant…”
BackgroundMethodResultInfluentialKurabayashi, T., Mizunuma, H., Kubota, T., & Hayashi, K. (2015) · Maturitas · doi:10.1016/j.maturitas.2015.08.015 · Cited by 42
Polycystic Ovarian Syndrome and Menopause in Forty Plus Women
Sharma, S., & Mahajan, N. (2021) · Journal of Mid-life Health · doi:10.4103/jmh.jmh_8_21 · Cited by 41
“[52,53] These studies have not demonstrated an increased risk of myocardial infarction or death from CVD or increased total mortality from any cause in women with PCOS.[52] Only the retrospective cohort study demonstrated an increased risk of stroke,[53] but the group also had a higher BMI, more diabetes, and more car…”
BackgroundInfluentialDalmasso, C., Maranon, R. O., Patil, C. N., Bui, E., Moulana, M., Zhang, H., Smith, A. D., Cardozo, L. L. Y., & Reckelhoff, J. F. (2016) · Endocrinology · doi:10.1210/en.2015-1617 · Cited by 41
“In contrast, Schmidt and colleagues (9) reported that hy-”
BackgroundResultInfluentialEffects of endocrine disorders on lipids and lipoproteins
Newman, C. B. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101667 · Cited by 40
Morbidity and mortality in PCOS: A prospective follow-up up to a mean age above 80 years
Forslund, M., Schmidt, J., Brännström, M., Landin‐Wilhelmsen, K., & Dahlgren, E. (2022) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2022.02.020 · Cited by 39
Self-citationPolycystic ovary syndrome and metabolic disorders: A review of the literature.
Ali, A. T., Al-ani, O., Al-Ani, F., & Guidozzi, F. (2022) · African Journal of Reproductive Health · doi:10.29063/ajrh2022/v26i8.9 · Cited by 38
Is There Really Increased Cardiovascular Morbidity in Women with Polycystic Ovary Syndrome?
Carmina, E., & Lobo, R. A. (2018) · Journal of Women s Health · doi:10.1089/jwh.2018.7162 · Cited by 38
Fernandez, E. D. T., Huffman, A. M., Syed, M., Romero, D. G., & Cardozo, L. L. Y. (2019) · Endocrinology · doi:10.1210/en.2019-00450 · Cited by 37
Wanderley, M. D. S., Pereira, L. C. R., Santos, C. B., da Cunha, V. S., & Neves, M. V. J. (2018) · Revista Brasileira Ginecologia e Obstetrícia · doi:10.1055/s-0038-1642634 · Cited by 37
Παππά, Θ., & Alevizaki, M. K. (2012) · European Journal of Endocrinology · doi:10.1530/eje-12-0215 · Cited by 36
Fauser, B. C. J. M., & Bouchard, P. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2935 · Cited by 36
“Based on the above-mentioned observations, firm position statements have been generated by the Androgen Excess Society—again published in JCEM—recommending that every woman with PCOS should undergo a 2-h ISSN Print 0021-972X ISSN Online 1945-7197 Printed in U.S.A. Copyright © 2011 by The Endocrine Society doi: 10.1210…”
BackgroundInfluentialHenney, A. E., Gillespie, C. S., LAI, J., Schofield, P. G., Riley, D. R. J., Caleyachetty, R., Barber, T. M., Miras, A. D., Dobbie, L. J., Hughes, D. M., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae481 · Cited by 36
“To date, limited prospective studies in women with PCOS analyze longer-term health consequences, extending into the postmenopausal period, contributing to heterogeneity in study findings (5, 6, 11, 20).”
Huang, G. T.-W., & Coviello, A. D. (2012) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e32835a000e · Cited by 35
Patil, C. N., Racusen, L. C., & Reckelhoff, J. F. (2017) · Physiological Reports · doi:10.14814/phy2.13461 · Cited by 34
Diabetes detection in women with gestational diabetes and polycystic ovarian syndrome
Hanna, F., Wu, P., Heald, A. H., & Fryer, A. A. (2023) · BMJ · doi:10.1136/bmj-2022-071675 · Cited by 35
Rees, E., Coulson, R.-M. K., Dunstan, F., Evans, W. D., Blundell, H. L., Luzio, S. D., Dunseath, G. J., Halcox, J., Fraser, A. G., & Rees, A. (2014) · Human Reproduction · doi:10.1093/humrep/deu180 · Cited by 34
“In contrast, our own and other studies have failed to demonstrate an increased incidence of cardiovascular events in pre- or post-menopausal women with PCOS (Wild et al., 2000; Schmidt et al., 2011; Morgan et al., 2012).”
ResultThe impact of ageing and menopause in women with polycystic ovary syndrome
Helvaci, N., & Yildiz, B. O. (2022) · Clinical Endocrinology · doi:10.1111/cen.14558 · Cited by 32
“Confirming this, in the 21‐year follow‐up study of the Gothenburg PCOS cohort, Schmidt et al.41 observed that, postmenopausal women with PCOS had a similar prevalence of T2DM compared to age‐matched control subjects of similar BMI.”
BackgroundMethodInfluential
Metadata
- Authors
- Schmidt, J., Landin-Wilhelmsen, K., Brännström, M., & Dahlgren, E.
- Affiliations
- Sahlgrenska University Hospital (SE)
- Corresponding author
- Schmidt, Johanna
- ORCID
- Brännström, Mats
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2011-12
- Volume
- 96
- Issue
- 12
- Pages
- 3794-3803
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2166647497
- Cited by
- 241
- References
- 44
- Citations by year
- 2026: 10 · 2025: 8 · 2024: 11 · 2023: 22 · 2022: 24 · 2021: 16 · 2020: 17 · 2019: 14 · 2018: 15 · 2017: 18 · 2016: 11 · 2015: 21 · 2014: 26 · 2013: 13 · 2012: 14
- FWCI
- 19.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Västra Götalandsregionen
- Vetenskapsrådet
- Sahlgrenska Universitetssjukhuset
- Health and Medical Care Committee of the Regional Executive Board, Region Västra Götaland
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- polycystic ovary syndrome, postmenopausal women, cardiovascular disease, cardiovascular risk factors, hypertension, triglycerides, myocardial infarction, stroke, mortality, metabolic syndrome, long-term follow-up
- MeSH terms
- Adult, Aged, Blood Glucose, Blood Pressure, Cardiovascular Diseases, Cholesterol, Female, Follow-Up Studies, Humans, Insulin, Middle Aged, Polycystic Ovary Syndrome, Registries, Risk Factors, Triglycerides, Incidence, Prevalence, Postmenopause
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.